Complexities in the development of cyclin-dependent kinase inhibitor drugs (Q34121518)

31 July 2017

1 reference

title

Complexities in the development of cyclin-dependent kinase inhibitor drugs (English)

1 reference

31 July 2017

Edward A Sausville

1

1 reference

31 July 2017

publication date

1 January 2002

1 reference

Trends in Molecular Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

8

1 reference

31 July 2017

issue

4 Suppl

1 reference

31 July 2017

page(s)

S32-7

1 reference

Principles of CDK regulation

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

The G2-phase DNA-damage checkpoint

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Identification of multiple cyclin subunits of human P-TEFb

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Upregulation of cyclin T1/CDK9 complexes during T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Cyclin-dependent kinase 5 promotes insulin exocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Identification of selective inhibitors of cyclin dependent kinase 4

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Cyclin-dependent kinase inhibitors for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Timing is everything: regulation of mitotic exit and cytokinesis by the MEN and SIN.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Specific protection against breast cancers by cyclin D1 ablation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

Homology probing: identification of cDNA clones encoding members of the protein-serine kinase family

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

A family of human cdc2-related protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902308-0

7 January 2021

10.1016/S1471-4914(02)02308-0

Identifiers

DOI

1 reference

31 July 2017

1 reference